Últimas noticias sobre Helius Medical Tech (NASDAQ:HSDT) Bolsa

Helius Medical Tech

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AMPG

AVGR

BIPC

CHEK

CREV

FDSB

HSDT

KORE

LAES

LIND

NCRA

NEUE

NVNI

RELI

SLGL

TIVC

TLRY

TOVX

Carbon Revolution lidera con un aumento del 62,4% en el premercado. ¿Qué otras acciones destacaron antes de la apertura?

Las acciones de Carbon Revolution (CREV) están subiendo un 62%; 20 acciones que se están moviendo en el premercado

Helius Medical Technologies, Inc. - Class A Common Stock

Helius Medical Technologies Inc

Helius Medical Technologies Inc Warrants (02/02/2026)

Achilles Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHL#NASDAQ">ACHL</a>) shares are trading higher on Tuesday after the company announced a $12 million deal with AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42669546/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca" rel="noreferrer noopener">and plans to cut jobs.</a>
The agreement involves the transfer of the commercial license for data and tumor samples from Achilles&#8217; TRACERx Non-Small Cell Lung Cancer (NSCLC) study to AstraZeneca.
The million deal signals the conclusion of Achilles&#8217; strategic review, which was announced in September 2024.
In the wake of the deal&#8217;s completion, Achilles also rvealed plans to reduce its employee headcount and trim its Board of Directors, while staying compliant with Nasdaq and SEC requirements.
&#8220;Achilles now plans to undertake additional measures, including a further reduction in employee headcount and a decrease in the size of its Board of Directors, while remaining compliant with Nasdaq and SEC requirements,&#8221; the company noted.
Also Read: <a href="https://www.benzinga.com/news/large-cap/24/12/42668623/american-airlines-resolves-nationwide-flight-grounding-on-christmas-eve-shares-rebound-after-brief-selloff">American Airlines Lifts Christmas Eve Grounding, Shares Bounce Back</a>
TRACERx, a study led by Professor Charles Swanton at University College London (UCL), has collected extensive genetic data from over 3,200 tumor samples from more than 800 lung cancer patients.
This multi-region, multi-time-point sequencing offers deep insights into cancer evolution and treatment responses.
As part of the deal, AstraZeneca will also take over Achilles&#8217; Material Acquisition Platform (MAP), which houses tumor samples and data collected from nearly 300 cancer patients across various solid tumor indications such as lung, melanoma and breast cancer.
&#8220;We are pleased that as a leader in Oncology, AstraZeneca recognizes the scientific value of our TRACERx and MAP assets,&#8221; said Dr. Iraj Ali, CEO of Achilles Therapeutics.
The company believes these assets have significant potential to aid in developing improved cancer therapies.
Price Action: ACHL shares are trading higher by 7.01% to $1.050 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42660092/microstrategy-sinks-after-nasdaq-100-inclusion-bitcoin-bet-under-fire" target="_blank" rel="noreferrer noopener">MicroStrategy Sinks After Nasdaq 100 Inclusion: Bitcoin Bet Under Fire?</a></li>
</ul>
Photo by Johaehn from Pixabay

Equities

General

ACHL

Achilles Therapeutics Announces $12M AstraZeneca Deal, Plans Job Cuts

Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) shares are hitting new highs on Tuesday. Here&#8217;s a look at <a href="https://www.benzinga.com/markets/equities/24/12/42668157/stanley-druckenmiller-dumps-streets-hottest-ai-stocks-heres-what-the-billionaire-investor-is-betting-on-next">what&#8217;s going on</a>. 
What To Know: Palantir shares are up more than 380% since the start of the year, driven largely by the company&#8217;s positioning in the AI space. 
The rally in Palantir shares accelerated at the beginning of November after the company reported&nbsp;<a href="https://www.benzinga.com/news/earnings/24/11/41730179/palantir-q3-earnings-revenue-beat-eps-beat-customers-up-39-raises-guidance-results-driven-by-unrele" target="_blank" rel="noreferrer noopener">strong quarterly results</a>&nbsp;driven by&nbsp;&#8220;unrelenting&#8221; AI demand.&nbsp;
Revenue jumped 30% year-over-year on continued strength in the U.S. and customer count grew 39% after the company closed 104 deals worth over $1 million during the quarter.
&#8220;The growth of our business is accelerating, and our financial performance is exceeding expectations as we meet an unwavering demand for the most advanced artificial intelligence technologies from our U.S. government and commercial customers,"&nbsp;Alex Karp, co-founder and CEO of Palantir, said in a letter to shareholders last month.
Check This Out: <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42671903/investors-aggressively-bought-stocks-etfs-despite-fed-volatile-week-bank-of-america-reveals-largest-inflows-since-2017">Investors Aggressively Bought Stocks, ETFs In Volatile Fed Week: Bank Of America Reveals Largest Inflows Since 2017</a>
Over the weekend, the Financial Times <a href="https://www.ft.com/content/6cfdfe2b-6872-4963-bde8-dc6c43be5093">reported</a> that Palantir and defense technology company Anduril are communicating with several competitors about the potential of forming a consortium to make a joint bid on U.S. government contracts.
The report indicates that SpaceX and OpenAI are among the companies in talks to join. The group is planning to announce itself publicly as soon as January, people with knowledge of the matter said. 
"We are working together to provide a new generation of defense contractors," one person involved in organizing the group reportedly said. 
The Financial Times further reported that tie-ups between some tech groups expected to be involved with the consortium have already started. Palantir&#8217;s AI platform was integrated with Anduril&#8217;s autonomous software earlier this month and Anduril has linked its counter-drone systems with OpenAI models.
Palantir announced last week that it extended its long-standing partnership with the U.S. Army&nbsp;through 2028. The four-year agreement extension is valued at more than $400 million and has a total available ceiling of approximately $619 million. 
By leveraging Palantir&#8217;s software, the U.S. Army is able to create AI-enabled data solutions to analyze information from multiple data sources, enabling operational efficiencies and optimizing business processes.
PLTR Price Action: <a href="http://benzinga.com/quote/pltr">Palantir shares </a>were trading at all-time highs at last check. The stock was up 1.31% at $81.79 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

PLTR

Palantir Stock Is Trading At All-Time Highs: What's Going On?

The Biden administration withdrew two major student loan forgiveness plans Friday, just weeks before President-elect Donald Trump returns to the White House. Here's a look at what it means for borrowers and student <a href="https://www.benzinga.com/markets/equities/24/12/42635567/biden-student-loan-forgiveness-tops-180-billion-with-latest-relief">loan service providers.</a> 
The Details: The Education Department posted notices in the Federal Register that it was withdrawing two proposals that could have reduced student loan debt for millions of borrowers, including those with financial hardship and those who have been in repayment for years, CNBC reported. 
Read Next: <a href="https://www.benzinga.com/news/24/12/42669113/waymos-autonomous-vehicles-are-safer-than-human-drivers-report">Waymo&#8217;s Autonomous Vehicles Are Safer Than Human Drivers: Report</a>
The department wrote that it was withdrawing the proposed rules due to "operational challenges in implementing the proposals." It also said it would focus its resources on "helping at-risk borrowers return to repayment successfully" as the administration prepares to leave office in the next month.&nbsp;
"The Biden administration knew that the proposals for broad student loan forgiveness would have been thwarted by the Trump administration," higher education expert Mark Kantrowitz<a href="https://www.cnbc.com/2024/12/23/student-loan-forgiveness-plans-withdrawn-by-biden-administration.html"> told</a> CNBC.&nbsp;
What Else: Also on Friday, the Department of Education announced another $4.28 billion in<a href="https://www.ed.gov/about/news/press-release/biden-harris-administration-approves-additional-428-billion-student-debt-relief-nearly-55000-public-service-workers-0"> loan forgiveness</a> for nearly<a href="https://www.benzinga.com/topic/student-debt"> 55,000 public service workers</a> which brought the total amount of student loan forgiveness under the Biden administration to $180 billion.
Education Secretary Miguel Cardona emphasized the administration's commitment to student loan relief for public service workers in a statement Friday. 
"Four years ago, the Biden-Harris Administration made a pledge to America&#8217;s teachers, service members, nurses, first responders, and other public servants that we would fix the broken Public Service Loan Forgiveness Program, and I&#8217;m proud to say that we delivered," Cardona said.
Loan Servicers: The administration's withdrawal of the additional loan forgiveness proposals is potentially a positive development for student loan providers including SoFi Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>), Navient Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAVI#NASDAQ">NAVI</a>) and SLM Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>)&nbsp;
Student loan providers would have lost revenue if Biden's student loan forgiveness plans had gone through. 
Additionally, the rollout of forgiveness programs often requires servicers to update systems, retrain staff and manage complex transitions, all of which would increase expenses.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42564443/santa-came-early-with-rate-cut-but-federal-reserve-brings-coal-next-year-experts-weigh-in-on-rate-cut-feds-2025-projections">&#8216;Santa Came Early&#8217; But Fed Brings &#8216;Coal Next Year&#8217;: Experts Weigh In On Interest Rate Cut, 2025 Projections</a></li>
</ul>
Image: Shutterstock.

Government

Education

Politics

Legal

NAVI

SOFI

Biden Dumps Student Loan Forgiveness Plans: What It Means For Borrowers, Loan Providers Like SoFi

Carmell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares are trading higher after it entered into a securities purchase agreement <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42668635/carmell-announces-pipe-investment-from-existing-and-new-investors-to-support-commercial-build-out" rel="noreferrer noopener">with new and existing investors</a>.
The agreement involves the issuance and sale of 8,065,210 shares of common stock and an equal number of five-year warrants, both priced at $0.23 per share, in a private placement.
The transaction is expected to generate gross proceeds of $1.85 million before offering expenses and fees.
If the warrants are exercised, Carmell could receive an additional $1.85 million.
The Private Placement was priced slightly above CTCX&#8217;s closing price on Dec. 23, 2024.
Following the closing of the Private Placement, Carmell Corporation will have approximately 29 million shares of common stock outstanding.
The warrants can be exercised starting the trading day after the Stockholder Approval Date and continue until the fifth anniversary of the warrant issue date.
The warrants allow for the purchase of up to 8.1 million shares of Carmell&#8217;s common stock at an exercise price of $0.23 per share.
The closing of the Private Placement is subject to customary conditions.
Price Action: CTCX shares are up 20% at $0.27 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">Warren Buffett Heads Into 2025 With $325 Billion Cash Pile, His Largest in Over Three Decades: Expert Says It &#8216;Will Provide An Opportunity For The Successors To Make Their Own Mark&#8217;</a></li>
</ul>
Photo: Shutterstock

Financing

Small Cap

CTCX

Why Biotechnology Company Carmell Shares Are Seeing Blue Skies Tuesday?

Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) has outperformed the market over the past 10 years by 1.41% on an annualized basis producing an average annual return of 12.59%. Currently, Agilent Technologies has a market capitalization of $38.44 billion. 
Buying $100 In A: If an investor had bought $100 of A stock 10 years ago, it would be worth $327.79 today based on a price of $134.60 for A at the time of writing.
<h3>Agilent Technologies's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735058734_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Agilent Technologies Stock In The Last 10 Years

WIIM

EVTL

Vertical Aerospace shares are trading higher. The company announced it has finalized an investment agreement for up to $50M in new funding.

BREA

Brera Holdings Shares Resume Trade

Brera Holdings Shares Resume Trade Then Again Halted On Circuit Breaker To The Upside, Stock Now Up 52.8%

Graphjet Technology Shares Halted On Circuit Breaker To The Downside, Stock Now Up 164.3%

Over the past year, OpenAI has dropped not-so-subtle hints about its revived interest in robotics: investing in startups developing hardware and software for robots such as Figure and Physical Intelligence and rebooting its internal robotics software team, which it had disbanded four years ago. Now, OpenAI could be taking that interest to the next level. The company has recently considered developing a humanoid robot, according to two people with direct knowledge of the discussions. &nbsp;As a refresher, humanoid robots typically have two arms and two legs, distinguishing them from typical robots in a warehouse or factory that might have a single arm repeatedly performing the same task on an assembly line. Developers of humanoid robots think it will be easier for them to handle tasks in the physical world—which is tailored to humans—than it would be to change our physical environments to suit new robots. Don't get too excited yet, though: Any potential humanoid robot seems to be a lower priority for OpenAI than a number of its other technologies and products, such as its highly praised reasoning models and an agent that could help automate all manner of software engineering and analysis tasks, one of these people said.
<a href="https://www.theinformation.com/articles/openai-has-discussed-making-a-humanoid-robot" title="https://www.theinformation.com/articles/openai-has-discussed-making-a-humanoid-robot">https://www.theinformation.com/articles/openai-has-discussed-making-a-humanoid-robot</a> &nbsp;

MSFT

TSLA

'OpenAI Has Discussed Making a Humanoid Robot' - The Information

Graphjet Technology Shares Resume Trade

Brera Holdings Shares Halted On Circuit Breaker To the Upside, Stock Now Up 29.9%

According to widely-followed crypto influencer &#8216;artchick,&#8217; Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) will not be the main meme coin <a href="https://www.benzinga.com/money/bitcoin-price-prediction">beneficiaries of a rally</a>.
The influencer&#8217;s forecast hinges on Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) maintaining its momentum and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) outperforming. 
Her top five include Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) with a $1 trillion target, Mog (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">MOG</a>) at $200 billion, Popcat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">POPCAT</a>) and Bonk (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BONK</a>) at $25 billion each. Among the newer entrant, Goatseus Maximus (CRYPTO: GOAT), Fartcoin also made it to the list. Artchick also added Dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>) with $25 billion price target to the list.
She says that while these valuations might feel absurd right now, crypto isn't operating on "normal cycles" anymore. "We're nearing escape velocity", and the market dynamics are evolving rapidly.
While ETH and SOL face inflation and execution risks, the meme coins traded on these chains are inherently different—they're pure, antifragile digital assets. 
By late 2025, the trader <a href="https://x.com/digitalartchick/status/1871365793596035105">believes</a> they'll be among the most sought after and resilient asset classes ever created.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42626582/dogecoin-shiba-inu-absent-from-2024s-top-performing-meme-coins-heres-who-made-the-cut">Dogecoin, Shiba Inu Absent From 2024&#8217;s Top-Performing Meme Coins: Here&#8217;s Who Made The Cut</a>
Artchick emphasizes that meme coin investing requires careful position sizing to endure high volatility and sharp drawdowns. She explains: &#8220;If you're overexposed, you're not going to make it. Volatility and shakeouts strengthen these memes. See you at the top.&#8221;
Her analysis suggests meme coins could emerge as one of the most resilient and sought-after digital asset classes by 2025.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42645811/dogecoin-shiba-inu-could-underperform-stronger-cryptos-trader-warns-heres-why">Dogecoin, Shiba Inu Could Underperform Stronger Cryptos, Trader Warns: Here&#8217;s Why</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BONK

$BTC

$DOGE

$ETH

$MOG

$PEPE

$POPCAT

$SHIB

$SOL

$WIF

Bitcoin's Outperformance Could Leave Dogecoin, Shiba Inu Sidelined, But Propel Pepe, Dogwifhat, Bonk To New Highs

Key Highlights of the Acquisition Process:
<ol>
<li>Investments and Share Purchase Agreement ("SPA") – Brera Holdings has agreed to acquire a majority stake in Juve Stabia through share capital and reserve increases in the Club.&nbsp; These will be made by Brera via cash payments and issuances of BREA's shares in a three-step process that ensures a seamless transition and continuity in club management. These three steps, upon conclusion, will give Brera Holdings 22%, 38%, and ~52% ownership of the Club. Upon completion of these three steps, Brera will be the Club's majority shareholder, and a Shareholder Agreement with the current sole owner, Andrea Langella, will further enable integration into its multi-club framework. The first step, giving Brera 22% ownership, is expected to conclude by December 31, 2024.</li>
<li>Milestone-Based Compensation – The SPA includes provisions for additional compensation to Mr. Langella tied to performance-based milestones, such as qualification for Serie B promotion playoffs and promotion to Serie A. These incentives align Brera's interests with Juve Stabia's competitive success, reinforcing a focus on operational excellence.</li>
<li>Final Closing and Majority Control – The acquisition will conclude with a third and final closing, scheduled for March 31, 2025. At that point, Brera Holdings will secure ~52% ownership, establishing Brera as the controlling shareholder and enabling immediate integration of the Club into the Company's multi-club framework. This phased approach ensures a seamless transition and continuity in Club management and prepares the Club for an IFRS audit according to the PCAOB guidelines for SEC disclosure filings.</li>
</ol>

Brera Holdings Outlines 3-Step Plan To Acquire 52% Stake In Serie B Club Juve Stabia, Integrating It Into Multi-Club Model To Drive Value Creation; Initial 22% Stake Expected By December 31, 2024, With Full Majority Control By March 2025; No Financial Terms Disclosed

Clearmind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>) saw its shares rise on Tuesday after announcing that it has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, a drug <a href="https://www.benzinga.com/movers" target="_blank" rel="noreferrer noopener">targeting alcohol use disorder (AUD)</a>.
This approval marks a significant milestone in the company&#8217;s FDA-regulated clinical program, and the trial will be conducted at Yale School of Medicine&#8217;s Department of Psychiatry, led by Anahita Bassir Nia, an expert in psychiatry and addiction medicine.
The trial will evaluate the safety, tolerability, and efficacy of CMND-100, a proprietary investigational drug designed to reduce alcohol cravings and consumption in individuals with moderate to severe AUD.
Adi Zuloff-Shani, CEO of Clearmind Medicine, emphasized the importance of this step, noting that alcohol use is a leading preventable cause of death globally, responsible for 2.6 million deaths annually.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/24/12/42669198/whats-going-on-with-nio-stock-on-tuesday" rel="noreferrer noopener">What&#8217;s Going On With NIO Stock On Tuesday?</a>
Current treatment options are limited, with low efficacy and patient compliance.
Clearmind aims to address this gap with CMND-100, offering a potential solution for treating AUD that could significantly improve patient outcomes.
The trial is expected to provide critical data to support the advancement of CMND-100 through its clinical pipeline, offering hope for more effective treatment options for those struggling with alcohol addiction.
According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>, CMND stock has lost over 6% in the past month. Investors can gain exposure to the stock via AdvisorShares Psychedelics ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSIL#NYSE">PSIL</a>).
Price Action: CMND shares are trading higher by 35% to $1.64 at last check Tuesday.
Read Action:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/12/42664692/bitcoin-flat-ethereum-dogecoin-spike-ahead-of-christmas-analyst-says-decline-in-btc-dominance-leaves-room-for-altcoins-to-pick-up" target="_blank" rel="noreferrer noopener">Bitcoin Flat, Ethereum, Dogecoin Spike Ahead Of Christmas: Analyst Says Decline In BTC Dominance Leaves ‘Room For Altcoins To Pick Up'</a></li>
</ul>
Photo: Shutterstock

Health Care

CMND

PSIL

Why Is Penny Stock Clearmind Gaining Today?

Solana&#8216;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) <a href="https://www.benzinga.com/money/solana-price-prediction">growth over the past two years</a>, marked by a staggering 2,143% price increase, is rooted in a substantial $55 billion influx of new capital, according to a recent analysis by Glassnode.
The <a href="https://insights.glassnode.com/analyzing-the-movement-of-capital-across-the-solana-asset/?utm_campaign=SOL_Stage2&amp;utm_medium=email&amp;utm_source=SOL_launch">report,</a> released earlier in the week, delves into the network's underlying dynamics, revealing robust investor demand that, despite profit-taking, hasn&#8217;t reached levels traditionally associated with market tops.
Solana's journey from a low of $9.64 following the FTX collapse to its current position as a major crypto contender is a story of notable recovery. 
The Glassnode report highlights this outperformance, noting that Solana has not only eclipsed Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) in price appreciation but has also consistently attracted more capital, capturing significant market attention. 
This surge is not merely speculative; it&#8217;s backed by a tangible shift in investor preference.
The analysis reveals a critical detail: new capital flowing into Solana is outpacing that of Ethereum for the first time. 
This is measured by the &#8220;Hot Realized Cap,&#8221; which tracks capital held by newly active addresses. 
The data underscores a growing appetite for Solana, particularly among new market entrants, a factor that propelled the asset&#8217;s growth at the start of 2024. 
This surge in capital inflow shows the network&#8217;s appeal.
Glassnode&#8217;s report goes on to track the on-chain capital flow, revealing a consistent net positive inflow into Solana since September 2023. 
This consistent liquidity injection has been the backbone of Solana's price appreciation, with daily inflows peaking at $776 million.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42667932/did-vladimir-putin-just-ban-bitcoin-mining-in-russia-the-devil-is-in-the-details">Did Vladimir Putin Just Ban Bitcoin Mining In Russia? The Devil Is In The Details</a>
This indicates a healthy demand-side dynamic essential for sustaining growth.
The analysis also addresses the natural phenomenon of profit-taking that occurs during bull markets. 
Glassnode's breakdown shows a balanced distribution of profit taking across different investor cohorts, from short-term holders to those holding for longer periods of 6-12 months. 
This highlights the broad appeal of Solana as an investment for different types of market participants. 
As a result of these inflows, Solana has seen its Realized Cap rise from $22B to $77B.
Despite the rapid price increase, the report posits that the market isn&#8217;t overheated.
Using the MVRV ratio as a benchmark, the analysis notes that current investor profitability is within reasonable bounds, not yet reaching the extreme levels historically seen at market tops. 
This suggests that there is potential for further upward movement before the market becomes overextended.
Glassnode&#8217;s report portrays a market driven by solid capital inflows and a broad base of investors. 
Solana&#8217;s recovery is not just a story of price action, but also one of substantial liquidity and expanding adoption. 
While vigilance is needed, the current data suggests a sustainable growth trajectory, not an imminent bubble. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42667518/deribit-eyes-growth-in-asset-backed-crypto-with-pax-gold-debut">Deribit Eyes Growth In Asset-Backed Crypto With Pax Gold Debut</a></li>
</ul>
Image: Shutterstock

Solana Surged 2,000% In 2 Years, But It Could Go Even Higher: Report

Graphjet Technology Shares Halted On Circuit Breaker To The Upside, Stock Now Up 226%

Navitas Semiconductor's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NYSE">NVTS</a>) short percent of float has fallen 15.63% since its last report. The company recently reported that it has 23.48 million shares sold short, which is 18.25% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.91 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Navitas Semiconductor Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735057821_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Navitas Semiconductor has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Navitas Semiconductor's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Navitas Semiconductor's peer group average for short interest as a percentage of float is 8.82%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

NVTS

(NVTS) - Analyzing Navitas Semiconductor's Short Interest

Intellia Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NYSE">NTLA</a>) short percent of float has risen 15.57% since its last report. The company recently reported that it has 18.91 million shares sold short, which is 21.15% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.83 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Intellia Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735057816_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Intellia Therapeutics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Intellia Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Intellia Therapeutics's peer group average for short interest as a percentage of float is 13.63%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

NTLA

Peering Into Intellia Therapeutics's Recent Short Interest

Ares Capital's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NYSE">ARCC</a>) short percent of float has risen 10.7% since its last report. The company recently reported that it has 17.31 million shares sold short, which is 2.69% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.48 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ares Capital Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735057811_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ares Capital has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ares Capital's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ares Capital's peer group average for short interest as a percentage of float is 3.15%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ARCC

Looking Into Ares Capital's Recent Short Interest

Helius Medical Technologies GAAP EPS of -$0.64 misses by $0.14, revenue of $0.18M beats by $0.03M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Helius Medical Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/hsdt-stock-quote/">HSDT</a>) just reported results for the second quarter of 2024.<ul><li>Helius Medical Tech reported earnings per share of -64 cents. This was below the analyst estimate for EPS of -50 cents.</li><li>The company reported revenue of $182,000.</li><li>This was 21.33% better than the analyst estimate for revenue of $150,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/hsdt-stock-earnings-helius-medical-tech-for-q2-of-2024/">HSDT Stock Earnings: Helius Medical Tech Misses EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

HSDT Stock Earnings: Helius Medical Tech Misses EPS, Beats Revenue for Q2 2024

Helius Medical Technologies, Inc. (HSDT) Q2 2024 Earnings Call Transcript

Helius Medical Technologies Inc (HSDT) has disclosed a new risk, in the Share Price & Shareholder Rights category. Helius Medical Technologies Inc....

Helius Medical Technologies Faces Nasdaq Delisting Risk Due to Stock Price Non-Compliance

Helius Medical Technologies ( ($HSDT) ) just unveiled an update. Helius Medical Technologies is actively pursuing strategic alternatives to enhance...

Helius Medical Explores Strategic Alternatives Amid Challenges

Helius Medical (HSDT) Technologies has initiated a process, in consultation with its financial and legal advisors, to explore a range of strategic ...

Helius Medical announces exploration of strategic alternatives

Helius Medical (HSDT) provided updates on its efforts to achieve fair market access for its Portable Neuromodulation Stimulator – PoNS – device. "W...

Helius Medical provides update on PoNS device pricing regulation

In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Hold rating on Helius Medical Technologies (HSDT – Research Report)....

Helius Medical Technologies (HSDT) Gets a Hold from Maxim Group

Helius Medical Technologies Inc ( ($HSDT) ) has released its Q3 earnings. Here is a breakdown of the information Helius Medical Technologies Inc pr...

Helius Medical Technologies Reports Q3 2024 Earnings

Helius Medical (HSDT) Technologies announced the first PoNS System sale to the VA Healthcare System. The PoNS System sale through our distributor, ...

Helius Medical announces first PoNS System sale to VA Healthcare System

HSDTW

Press Releases

Helius Medical Technologies, Inc. Completes Site Participation Enrollment for its U.S. Registrational Program in Stroke

Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024

Earnings

Helius Medical Technologies, Inc. Reports Second Quarter 2024 Financial Results

Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study

Helius Medical Technologies, Inc. Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator (PoNS®) Controller and Mouthpiece

Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference

Helius Medical Technologies, Inc. Announces Exploration of Strategic Alternatives

Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device

Helius Announces First Portable Neuromodulation Stimulator (PoNS®) System Sale to the Veterans Affairs (VA) Healthcare System

Comments

Helius Medical Tech

Noticias

Últimas noticias sobre Helius Medical Tech (NASDAQ:HSDT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL